Drugs / Eleclazine
Eleclazine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 1 missed | ||||||
| Phase 1 | NCT02365506 | Jul 2015 → May 2016 | long QT syndrome 2 | Gilead Sciences | Completed | Missed primary |
| Phase 1 | NCT02441829 | May → Dec 2015 | long QT syndrome | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02412098 | Mar 2015 → Apr 2016 | long QT syndrome | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02365532 | Feb → May 2015 | long QT syndrome | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01849003 | May 2013 → Nov 2014 | long QT syndrome | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01847391 | May → Nov 2013 | ischemic disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02377336 | May 2015 → Aug 2016 | ischemic disease | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02104583 | Sep 2014 → Sep 2016 | cardiac rhythm disease | Gilead Sciences | Completed | Missed primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02291237 | Feb 2015 → Jan 2017 | hypertrophic cardiomyopathy | Gilead Sciences | Terminated | Missed primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02300558 | Dec 2014 → Dec 2016 | long QT syndrome 3 | Gilead Sciences | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-05-09 | Gilead Sciences | Results Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome gilead.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-05-09 | Gilead Sciences | Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome gilead.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eleclazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02412098 ↗ |
| Known as | Eleclazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707392 ↗ |
| Known as | GS-6615 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01849003 ↗ |
| Modality | Small molecule | — CHEMBL3707392 ↗ |
| Route | Oral | “administered orally once daily” NCT01847391 ↗ |